Our results have led us to conclude that the Crizotinib—ALK binding measurable by CETSA is useful in predicting Crizotinib sensitivity in ALK+ cancer cells, and Crizotinib—ALK binding is in turn dictated by structure of ALK and some of its binding partners. This evidence concerns the gene ALK and cancer.